IL-28R alpha/IFN-lambda R1 Products

Description

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAi's unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

Bioinformatics

Product By Gene ID

163702

Alternate Names

class II cytokine receptor CRF2/12 CRF2/12 CRF2-12 Cytokine receptor class-II member 12 Cytokine receptor family 2 member 12 IFN-lambda R1 IFN-lambda receptor 1 IFN-lambda-R1 IFNLR IFNLR1 IL-28 R alpha IL-28 receptor subunit alpha IL28R alpha IL-28R1 IL28RA IL-28Ra IL-28R-alpha Interferon lambda receptor 1 interferon lambda, receptor 1 interleukin 28 receptor A interleukin 28 receptor, alpha (interferon, lambda receptor) interleukin 28 receptor, alpha interleukin or cytokine receptor 2 interleukin-28 receptor subunit alpha LICR2 Likely interleukin or cytokine receptor 2

Research Areas for IL-28R alpha/IFN-lambda R1

Find related products by research area and learn more about each of the different research areas below.

Apoptosis
Cytokine Research